Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Sisunatovir - ReViral

Next Previous
Drug Profile

Sisunatovir - ReViral

Alternative Names: PF-07923568; RV-521; RV521.HCl; Sisunatovir hydrochloride - ReViral

Latest Information Update: 03 Apr 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator ReViral
  • Developer Pfizer; ReViral
  • Class Antivirals; Benzimidazoles; Cyclopropanes; Fluorinated hydrocarbons; Indoles; Small molecules
  • Mechanism of Action Viral fusion protein inhibitors; Virus replication inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II/III Respiratory syncytial virus infections
  • Phase I Renal failure

Most Recent Events

  • 26 Feb 2024 Pfizer completes a phase I trials in Respiratory syncytial virus infections (In volunteers, In the elderly, In adults) in Belgium (PO) (NCT05994963) (EudraCT2023-505228-79-00)
  • 08 Feb 2024 Sisunatovir - ReViral receives Fast Track designation for Respiratory syncytial virus infections [PO] in USA prior to February 2024 (Pfizer pipeline, February 2024)
  • 07 Feb 2024 Pfizer completes a phase I pharmacokinetics trial (In volunteers) in USA (PO, Capsule) (NCT05857644)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top